Welcome to Rheum for Improvement, a website for people with lupus and the health professionals who care for them.New Flash Archive click here
Anti-interferon antibody important advance for treatment of lupus
A clinical trial with anti-interferon antibody treatment (anifrolumab) showed significant progress is reducing lupus disease activity, including cutaneous lupus. The treatment is administered intravenously and is most effective among patients with high disease activity. Anifrolumab inhibits all interferon responses, which are part of a normal immune response to infection. Consequently, a dose-dependent increase in the risk of infections, such as shingles and influenza, was observed. Nonetheless, the researchers believe the drug’s safety and tolerability are acceptable. Researchers hail anifrolumab as an important advance in the treatment of lupus. Read more here.